ALLO Nov 2024 7.500 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 09:30AM EDT. Market open.
| Previous close | 0.1100 |
| Open | 0.3000 |
| Bid | 0.1500 |
| Ask | 0.5000 |
| Strike | 7.50 |
| Expiry date | 2024-11-15 |
| Day's range | 0.3000 - 0.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | 29 |
ZacksAllogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag
Allogene (ALLO) reports drab first-quarter 2024 results. The company secures the development and marketing rights to its CD19 oncology program in Europe.
- GuruFocus.com
Allogene Therapeutics Inc (ALLO) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
Exploring Allogene's Q1 performance, strategic initiatives in oncology, and financial maneuvers amidst a challenging landscape.
ZacksAllogene Therapeutics (ALLO) Reports Q1 Loss, Lags Revenue Estimates
Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 0% and 47.62%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
© 2024 Yahoo. All rights reserved.